Back to Browse Journals » Clinical Ophthalmology » Volume 4
Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
Authors Patricia B Williams, Elizabeth Crandall, John D Sheppard
Published 1 September 2010 Volume 2010:4 Pages 993—1001
DOI https://doi.org/10.2147/OPTH.S13479
Review by Single-blind
Peer reviewer comments 3
Patricia B Williams1,2, Elizabeth Crandall2, John D Sheppard1,2
1Thomas R Lee Center for Ocular Pharmacology, 2Department of Ophthalmology, Eastern Virginia Medical School, Norfolk, A, USA
Abstract: Over 50% of patients who seek treatment for allergies present with ocular symptoms. Our current ability to control ocular allergic symptoms is greater than ever before. Newer dual-acting topical eyedrops attack multiple facets of the allergic cascade. Azelastine has antihistaminic effects providing immediate relief, mast cell stabilization providing early-phase intervention, and inhibition of expression and activation of anti-inflammatory mediators which characterize the late phase of the immune reaction. The ophthalmic eyedrop formulation is approved for treatment of allergic conjunctivitis in adults and children aged over 3 years. In clinical trials comparing azelastine with other dual-acting eyedrops, such as levocabastine and olopatadine, azelastine was reported to be slightly less efficacious and to sting briefly upon administration. Even so, many patients experienced the full benefit of symptom relief, and preferred azelastine. As a broad-spectrum drug, azelastine offers many desirable properties for management of ocular allergies. Because it can often produce maximal effect with just twice-daily dosing, azelastine is a particularly good choice for the allergic population in whom minimizing exposure to topical products and preservatives is a key concern.
Keywords: allergic conjunctivitis, dual acting anti-inflammatory, H1 receptor antagonism, mast cell stabilization, inflammatory mediator inhibition
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Readers of this article also read:
Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus
Jeong HR, An SSA
Clinical Interventions in Aging 2015, 10:1873-1879
Published Date: 19 November 2015
Mutations in presenilin 2 and its implications in Alzheimer’s disease and other dementia-associated disorders
Cai Y, An SSA, Kim SY
Clinical Interventions in Aging 2015, 10:1163-1172
Published Date: 14 July 2015
Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles
Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM
International Journal of Nanomedicine 2014, 9:1883-1889
Published Date: 16 April 2014
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C
Clinical Pharmacology: Advances and Applications 2014, 6:61-62
Published Date: 27 March 2014
Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon
Ashwanikumar N, Kumar NA, Nair SA, Kumar GS
International Journal of Nanomedicine 2012, 7:5769-5779
Published Date: 15 November 2012
A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone
Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W
International Journal of Nanomedicine 2012, 7:5719-5724
Published Date: 12 November 2012
Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy
Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS
International Journal of Nanomedicine 2012, 7:4077-4088
Published Date: 27 July 2012
Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs
Rao S, Song Y, Peddie F, Evans AM
International Journal of Nanomedicine 2011, 6:1245-1251
Published Date: 20 June 2011
Crystallization after intravitreal ganciclovir injection
Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant
Clinical Ophthalmology 2010, 4:709-711
Published Date: 14 July 2010
Characterization of complexation of poly (N-isopropylacrylamide-co-2-(dimethylamino) ethyl methacrylate) thermoresponsive cationic nanogels with salmon sperm DNA
Jim Moselhy, Tasnim Vira, Fei-Fei Liu, et al
International Journal of Nanomedicine 2009, 4:153-164
Published Date: 24 August 2009
